1. Health Strategies Group
1/2/2019
Health Strategies Group
TNF Inhibitors Continue to Lead In Brand Access Across Stakeholders; Orencia, Otezla, Costenyx Fall Next in Line
While stakeholders continue to consider Humira, Enbrel and Remicade as first line treatments for autoimmune diseases, slowly second-line product preferences, especially within other classes of therapy (e.g., IL-17 inhibitors and IL-23 inhibitors) are beginning to emerge.
Line of Therapy Assignments by Brand Align Across Payers and Providers
Payers: n=35 health plans; Providers: n=11 health systems, n=10 medical groups Source: Health Strategies Group, KnowledgeEdge, Brand Access Marketplace Dynamics, February 2018.